SCHEMBL31023988

SCHEMBL31023988

FC(F)(F)c1ccc(N(c2ccc3c(c2)OCO3)C2CCNCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.43
SLC6A4 P31645 5/20 0.41
SLC6A2 P23975 4/20 0.41
MAP2K4 P45985 1/20 0.40
TACR1 P25103 5/20 0.39
SLC6A3 Q01959 1/20 0.38
DYRK3 O43781 1/20 0.37
PIM1 P11309 1/20 0.37
DYRK1A Q13627 1/20 0.37
DYRK2 Q92630 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
CYP3A4 P08684 1/20 0.36
INSR P06213 1/20 0.36
IGF1R P08069 1/20 0.36
SRC P12931 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023847 0.90 SLC6A4 (0.45) SLC6A4SLC6A2TACR1SLC6A3DYRK3
SCHEMBL31023963 0.88 CYP3A4 (0.43) SLC6A4SLC6A2TACR1SLC6A3CYP3A4
SCHEMBL31023843 0.82 ALDH1A1 (0.40) HTR2CSLC6A4SLC6A2
SCHEMBL31023978 0.78 MGLL (0.47) CYP3A4
SCHEMBL31023740 0.78 CYP3A4 (0.41) SLC6A4SLC6A2CYP3A4
SCHEMBL18271346 0.77 SLC6A2 (0.56) HTR2CSLC6A4SLC6A2TACR1SLC6A3
SCHEMBL6307458 0.76 NPC1 (0.41) SLC6A4SLC6A3DYRK3PIM1DYRK1A
Hydrochloric Acid SCHEMBL18263754 0.76 SLC6A2 (0.55) HTR2CSLC6A4SLC6A2SLC6A3CYP3A4
Hydrochloric Acid SCHEMBL6188607 0.75 NPC1 (0.40) SLC6A4SLC6A3DYRK3PIM1DYRK1A
Hydrochloric Acid SCHEMBL6307331 0.75 NPC1 (0.40) SLC6A4SLC6A3DYRK3PIM1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL HTR2C 1754/4885SLC6A4 3471/4885SLC6A2 3242/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL HTR2C 1754/4885SLC6A4 3471/4885SLC6A2 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.